George Scangos - Biogen CEO and Director
| BIIB Stock | USD 216.13 1.31 0.61% |
CEO
Dr. George A. Scangos Ph.D. is no longer Chief Executive Officer Director of Biogen Inc. effective as January 6 2017. Dr. Scangos has served as our Chief Executive Officer since July 2010. Prior to that he served as the President and Chief Executive Officer of Exelixis Inc. a drug discovery and development company from 1996 to July 2010. From 1993 to 1996 Dr. Scangos served as President of Bayer Biotechnology where he was responsible for research business development process development manufacturing engineering and quality assurance of Bayers biological products. Before joining Bayer in 1987 Dr. Scangos was a professor of biology at Johns Hopkins University for six years where he is still an adjunct professor
| Age | 67 |
| Professional Marks | Ph.D |
| Address | 225 Binney Street, Cambridge, MA, United States, 02142 |
| Phone | 617 679 2000 |
| Web | https://www.biogen.com |
Biogen Management Efficiency
The company has return on total asset (ROA) of 0.0486 % which means that it generated a profit of $0.0486 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0805 %, meaning that it created $0.0805 on every $100 dollars invested by stockholders. Biogen's management efficiency ratios could be used to measure how well Biogen manages its routine affairs as well as how well it operates its assets and liabilities. At present, Biogen's Return On Capital Employed is projected to increase slightly based on the last few years of reporting. The current year's Return On Assets is expected to grow to 0.06, whereas Return On Tangible Assets are forecasted to decline to 0.08. At present, Biogen's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 21 B, whereas Non Currrent Assets Other are forecasted to decline to about 270.1 M.Similar Executives
| Found 13 records | CEO Age | ||
| Francesco Balestrieri | Novartis AG ADR | N/A | |
| Michael Ball | Novartis AG ADR | 62 | |
| Joseph Jimenez | Novartis AG ADR | 58 | |
| Emma Walmsley | GlaxoSmithKline PLC ADR | 55 | |
| Elizabeth Barrett | Novartis AG ADR | 56 | |
| Deborah Waterhouse | GlaxoSmithKline PLC ADR | N/A | |
| Paul Hudson | Novartis AG ADR | 51 | |
| Chris Ilsley | Novartis AG ADR | N/A | |
| Richard Saynor | Novartis AG ADR | 57 | |
| Olivier Brandicourt | Sanofi ADR | 62 | |
| Bruno Strigini | Novartis AG ADR | N/A | |
| Andrew Witty | GlaxoSmithKline PLC ADR | 50 | |
| Brian McNamara | GlaxoSmithKline PLC ADR | 49 | |
Management Performance
| Return On Equity | 0.0805 | ||||
| Return On Asset | 0.0486 |
Biogen Inc Leadership Team
Elected by the shareholders, the Biogen's board of directors comprises two types of representatives: Biogen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biogen. The board's role is to monitor Biogen's management team and ensure that shareholders' interests are well served. Biogen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biogen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christopher Viehbacher, CEO President | ||
| Robin Kramer, Chief Accounting Officer, Vice President | ||
| Paul McKenzie, Executive Vice President - Pharmaceutical Operations & Technology | ||
| Alfred Sandrock, Group Senior Vice President Chief Medical Officer | ||
| Spyros ArtavanisTsakonas, Senior Vice President Chief Scientific Officer | ||
| Alexander Denner, Independent Director | ||
| Natacha Gassenbach, Chief Affairs | ||
| Douglas Williams, Executive VP of RandD | ||
| JeanPaul Kress, Executive Vice President and Presidentident - International and Head of Global Therapeutic Operations | ||
| Eric Rowinsky, Independent Director | ||
| William Hawkins, Director | ||
| Charles Triano, Senior Relations | ||
| Kenneth Pietro, Executive Vice President - Human Resources | ||
| John Chiminski, Director | ||
| Adam Koppel, Senior Vice President and Chief Strategy Officer | ||
| Caroline Dorsa, Independent Director | ||
| Michael Ehlers, Executive Vice President of Research and Development | ||
| Ginger Gregory, Chief Human Resource Officer, Executive Vice President | ||
| Daniel Karp, Executive Vice President - Corporate Development | ||
| Anirvan Ghosh, Senior Vice President - Research and Early Development | ||
| Michael CPA, Executive CFO | ||
| Anabella Villalobos, Senior Vice President - Biotherapeutic & Medicinal Sciences (BTMS) | ||
| Stelios Papadopoulos, Independent Chairman of the Board | ||
| Adam Keeney, Executive Development | ||
| Robert Pangia, Independent Director | ||
| Matt Griffiths, Senior Vice President CIO | ||
| Jeffrey Capello, CFO, Executive Vice President | ||
| Jesus Mantas, Director | ||
| Richard Mulligan, Independent Director | ||
| Michel Vounatsos, Vice President and Chief Commercial Officer | ||
| Sanjay Jariwala, Senior Vice President - Worldwide Medical | ||
| Susan Esq, Executive Officer | ||
| George Scangos, CEO and Director | ||
| Adriana Karaboutis, Executive VP of Technology, Bus. Solutions and Corporate Affairs | ||
| Mark Hernon, Senior Vice President CIO | ||
| Stephen Sherwin, Independent Director | ||
| Chirfi Guindo, Executive Vice President Head of Global Marketing, Market Access and Customer Innovation | ||
| Susan Alexander, Executive Vice President Chief Legal Officer and Corporate Secretary | ||
| Catherine Steele, Senior Vice President - Corporate Affairs | ||
| Paul Clancy, CFO and Executive VP of Fin. | ||
| Steven Holtzman, Executive Vice President - Corporate Development | ||
| Nancy Leaming, Independent Director | ||
| Nicole Murphy, Head Technology | ||
| Michael Hencke, Head Relations | ||
| Lynn Schenk, Independent Director | ||
| Camille Lee, Senior Vice President - Alzheimer's Therapeutic Area | ||
| Brian Posner, Independent Director | ||
| Gregory Covino, Chief Accounting Officer, VP of Fin. and Controller | ||
| Alisha Alaimo, President America | ||
| John Cox, Executive VP of Pharmaceutical Operations and Technology |
Biogen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Biogen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0805 | ||||
| Return On Asset | 0.0486 | ||||
| Profit Margin | 0.12 % | ||||
| Operating Margin | 0.27 % | ||||
| Current Valuation | 37.15 B | ||||
| Shares Outstanding | 145.6 M | ||||
| Shares Owned By Insiders | 0.15 % | ||||
| Shares Owned By Institutions | 92.68 % | ||||
| Number Of Shares Shorted | 3.26 M | ||||
| Price To Earning | 14.83 X |
Pair Trading with Biogen
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biogen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biogen will appreciate offsetting losses from the drop in the long position's value.Moving together with Biogen Stock
| 0.74 | EVOK | Evoke Pharma | PairCorr |
| 0.7 | EWTX | Edgewise Therapeutics Financial Report 9th of May 2024 | PairCorr |
Moving against Biogen Stock
| 0.67 | HCWB | HCW Biologics | PairCorr |
| 0.66 | KRYS | Krystal Biotech Financial Report 13th of May 2024 | PairCorr |
| 0.65 | VKTX | Viking Therapeutics | PairCorr |
| 0.63 | DYAI | Dyadic International Financial Report 8th of May 2024 | PairCorr |
| 0.62 | OGN | Organon Financial Report 2nd of May 2024 | PairCorr |
The ability to find closely correlated positions to Biogen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biogen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biogen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biogen Inc to buy it.
The correlation of Biogen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biogen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biogen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biogen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biogen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Complementary Tools for Biogen Stock analysis
When running Biogen's price analysis, check to measure Biogen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biogen is operating at the current time. Most of Biogen's value examination focuses on studying past and present price action to predict the probability of Biogen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biogen's price. Additionally, you may evaluate how the addition of Biogen to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |
Is Biogen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biogen. If investors know Biogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biogen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.011 | Earnings Share 8 | Revenue Per Share 66.688 | Quarterly Revenue Growth (0.07) | Return On Assets 0.0486 |
The market value of Biogen Inc is measured differently than its book value, which is the value of Biogen that is recorded on the company's balance sheet. Investors also form their own opinion of Biogen's value that differs from its market value or its book value, called intrinsic value, which is Biogen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biogen's market value can be influenced by many factors that don't directly affect Biogen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biogen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biogen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.